An observational study in Atrial Fibrillation, sponsored by Medtronic Cardiac Ablation Solutions. Recruiting at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Medtronic Cardiac Ablation Solutions · Observational
PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.
PulseSelect is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months. Study visits will occur at 3, 6, 12, 24, and 36 months post-ablation, including required 24-hour Holter monitoring at 6, 12, 24, and 36 month visits. The PulseSelect™ PFA System used in this study is market approved and the ablation procedure will be performed according to hospital standard of care.
3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.
This study's planned enrollment of 580 is above the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Medtronic Cardiac Ablation Solutions is the lead sponsor of 37 studies on the registry; 10 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 8 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects 18 years or older with a planned procedure using commercially available PulseSelect™ PFA System
Exclusion Criteria
Ablation using the PulseSelect™ PFA system
Device: PulseSelect™ PFA system
Ablation using the PulseSelect™ PFA system
Device: PulseSelect™ PFA system
Ablation using the PulseSelect™ PFA system
Efficacy-Freedom from Atrial Fibrillation
Estimate the 36-month freedom from AF/AFL/AT recurrence following ablation using the PulseSelect™ PFA system.
Time frame: 36-months after the index ablation procedure
Safety- Freedom from Device/Procedure Related Adverse Events
Estimate the rate of major procedural complications for catheter ablation using PulseSelect™ PFA system.
Time frame: 6 months post-ablation]
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medtronic Cardiac Ablation Solutions